MICHELLE KRAMER, M.D., M.P.H.
GLOBAL HEAD OF DEVELOPMENT
Michelle Kramer, M.D., M.P.H. is the Global Head of Development for Neuroscience at Janssen Research & Development. With more than two decades of experience at Janssen and Johnson & Johnson, she has been involved with cross-therapeutic area clinical development including the immunology, neuroscience, infectious disease, oncology, cardiovascular and metabolic areas.
Most recently, Michelle led Medical Affairs for Neuroscience in the United States, where she oversaw the medical strategy for the INVEGA TRINZA® and INVEGA HAFYERA™ (paliperidone palmitate), SPRAVATO® (esketamine) and PONVORY™ (ponesimod) launches.
Michelle received a bachelor’s degree in Psychology at the University of Colorado, Boulder, as well as a doctorate in Medicine from Tuft’s University and a master’s in public health from Drexel University. She completed her residency in psychiatry at Duke University.